The use of fecal calprotectin as a biomarker in gastrointestinal disease.

Abstract

Abdominal discomfort including pain, bloating and diarrhea is common. It often arises from functional gastrointestinal disorders but may indicate inflammatory bowel disease (IBD). Calprotectin is an abundant neutrophil protein that is released during inflammation. When measured in feces, it can be used to differentiate between non-organic and inflammatory intestinal disorders, especially to identify IBD. Fecal calprotectin might also be useful to monitor patients with IBD under treatment and to predict the risk of recurrence of active disease prior to clinical relapse. The use of fecal calprotectin has been investigated in a number of gastrointestinal disorders other than IBD, for example, as screening test for colorectal cancer but the available data are limited. This article summarizes the current literature on the use of fecal calprotectin in clinical practice.

DOI: 10.1586/17474124.2014.869476
0100200300201520162017
Citations per Year

370 Citations

Semantic Scholar estimates that this publication has 370 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Burri2014TheUO, title={The use of fecal calprotectin as a biomarker in gastrointestinal disease.}, author={Emanuel Burri and Christoph Beglinger}, journal={Expert review of gastroenterology & hepatology}, year={2014}, volume={8 2}, pages={197-210} }